Abstract 4917
Background
The outcome of patients (pts) with BRAFV600 mutated advanced melanoma has dramatically improved by the introduction of TT and CPI. Pts responding on CPI have a high chance of long-term benefit. Pts with fast progressive disease (PD), high LDH and/or symptomatic (brain) metastasis often start with TT to induce a fast response, although most pts will relapse. Short-term TT increases intratumoral T-cell infiltration, which is diminished at PD. In addition, LDH level normalization and improvement of performance status (PS) during response to TT, might also argue for an earlier switch to CPI before PD.
Methods
We retrospectively identified pts that started treatment with TT and switched to subsequent CPI (either anti-PD-1 or anti-PD-1 plus anti-CTLA-4) at our institute. Progression was defined as radiological PD according to RECIST 1.1 or clinical PD defined by treating physician. Progression free survival (PFS) from start CPI (PFS-CPI), start TT (PFS-total) and overall survival (OS) were analyzed by Kaplan Meier methods and hazard ratio’s (HR) were calculated by Cox regression analysis.
Results
In total 74 pts were included; 37 pts switched to CPI prior to PD (noPD-switch) and 37 pts switched at PD (PD-switch); 32 vs 51% had brain metastases and 41 vs 49% had an elevated LDH. Median time on TT in the noPD-switch and the PD-switch group was 3.2 and 4.5 months, respectively. PFS-CPI was 2.5 months in the noPD-switch group vs 1.2 months in the PD-switch group (p = 0.11). OS was superior in the noPD-switch group with a median of 30.6 vs 14.1 months (p = 0.01). After correcting for previous treatment, LDH, PS, brain metastasis and number of metastatic sites, HR for OS was 0.48 (95% CI 0.22–1.01). Subgroup analysis revealed that pts with brain metastasis seem to benefit most from switch prior to PD. In pts that had reinduction of TT after CPI failure, the noPD-switch group benefitted longer from this subsequent TT line, although total time of benefit on TT (before and after CPI) was the same in both groups.
Conclusions
Pts that switch to CPI prior to PD upon TT have an increased OS, which can be attributed to the benefit from CPI and not the total time on TT.
Clinical trial identification
Legal entity responsible for the study
Netherlands Cancer Institute.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
J.V. van Thienen: Travel support: Roche. J.B.A.G. Haanen: Advisory boards: BMS, Merck, Roche, Neon Therapeutics, Pfizer, Ipsen; Grants to NKI from BMS, Merck, Novartis, Neon Therapeutics, outside the submitted work. C.U. Blank: Advisory boards: MSD, BMS, Roche, GSK, Novartis, Pfizer, Lilly; Grants: BMS, Novartis; Stock ownership: Verastem outside the submitted work. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract